Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 8/20 | 0.63 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | SNCA | P37840 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | WDR5 | P61964 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 2/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3209104 | 0.94 | GPR52 (0.72) | GPR52MRGPRX4SNCAAURKAKDM1A | |
| SCHEMBL1851733 | 0.89 | GPR52 (0.76) | GPR52MRGPRX4SNCAAURKAKDM1A | |
| SCHEMBL3209910 | 0.89 | GPR52 (0.69) | GPR52MRGPRX4SNCAKDM1AHPGDS | |
| SCHEMBL3206698 | 0.88 | GPR52 (0.55) | GPR52AURKAMETAP2CLK1 | |
| SCHEMBL3223077 | 0.86 | GPR52 (0.61) | GPR52SNCAKDM1AWDR5METAP2 | |
| SCHEMBL1855891 | 0.86 | GPR52 (0.57) | GPR52 | |
| SCHEMBL1851157 | 0.86 | GPR52 (0.57) | GPR52SNCAAURKA | |
| SCHEMBL7956422 | 0.85 | GPR52 (0.60) | GPR52SNCAAURKAWDR5METAP2 | |
| SCHEMBL1852756 | 0.85 | GPR52 (0.56) | GPR52 | |
| SCHEMBL1855888 | 0.85 | GPR52 (0.52) | GPR52METAP2CLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | GPR52 1/4885MRGPRX4 287/4885SNCA 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.